rs707824
|
|
|
0.810 |
GeneticVariation |
BEFREE |
A SNP in a novel non-HLA region on 6p23 (rs707824, P(NHL) = 5.72×10(-7)) was suggestive of an association conferring susceptibility to lymphoma.
|
23349640 |
2013 |
rs11540652
|
|
|
0.720 |
GeneticVariation |
BEFREE |
This was associated with a twofold higher T-lymphoma proliferation in R248Q/- mice compared with G245S/- and null mice.
|
23538418 |
2013 |
rs11540652
|
|
|
0.720 |
GeneticVariation |
BEFREE |
We previously showed that the HSP90 inhibitor ganetespib potently suppresses T-lymphoma initiation and progression and extends overall survival (OS) in hotspot knockin mice expressing the p53 gain-of-function mutants R175H and R248Q (mutp53) by 30-59%.
|
28300840 |
2017 |
rs267601394
|
|
|
0.720 |
GeneticVariation |
BEFREE |
As EZH2 mutations often coincide with other mutations in lymphoma, we combined the expression of EZH2(Y641F) by crossing these transgenic mice with Eµ-Myc transgenic mice.
|
24802772 |
2014 |
rs267601394
|
|
|
0.720 |
GeneticVariation |
BEFREE |
These results suggest that Ezh2(Y641F) induces lymphoma and melanoma through a vast reorganization of chromatin structure, inducing both repression and activation of polycomb-regulated loci.
|
27135738 |
2016 |
rs1057519833
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Herein, we identify mutation of EZH2 A677 to a glycine (A677G) among lymphoma cell lines and primary tumor specimens.
|
22323599 |
2012 |
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Myd-88 L265P constitutive activating mutations are present in at least some cases of the diffuse large B-cell lymphoma form of vitreoretinal lymphoma.
|
25768255 |
2015 |
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Suppressing IL-10 significantly reduced STAT3 activation in both MYD88 WT and MYD88 L265P m</spa</span>n>utant lymphomas</span>.
|
30253331 |
2018 |
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA.
|
30204732 |
2019 |
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MYD88 L265P mutation has been reported in ∼90% of Waldenström's Macroglobulinemia (WM) patients and immunoglobulin M (IgM) monoclonal gammopathies of uncertain significance (MGUS), as well as in some cases of lymphoma and chronic lymphocytic leukemia.
|
24992174 |
2015 |
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
With clinical trials regarding their efficacy rapidly expanding to NHLs, we also discuss potential combinations of immune checkpoint inhibitors with the described targeted chemotherapies of L265P signaling networks, and/or with the above immunological approaches as potential ways of targeting MYD88-mutated lymphomas in the future.
|
30203262 |
2018 |
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Recurrent lymphoma-associated mutations, particularly Leu265Pro (L265P), within the MyD88 Toll/interleukin-1 receptor (TIR) domain sustain lymphoma cell survival due to constitutive nuclear factor κB signaling.
|
25359991 |
2014 |
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The MYD88 missense mutation c.794T>C, p.Leu265Pro, is found in patients with Waldenstörm's macroglobulinemia and lymphoma.
|
28042684 |
2017 |
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In order to evaluate whether the presence of the recently described MYD88 L265P mutation in patients with Waldenström's macroglobulinemia (WM) is contributory to SS-associated lymphomagenesis, a quantitative allele-specific PCR method was performed in peripheral blood derived from 90 SS patients as well as in minor salivary gland tissues derived from 12 primary SS patients with or without lymphoma.
|
24153350 |
2014 |
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Four cases of small lymphocyte-predominant benign PE from patients without history of lymphoma were examined and were all negative for MYD88 L265P mutation.
|
31556196 |
2019 |
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
HLA class I-restricted <i>MYD88</i> L265P-derived peptides as specific targets for lymphoma immunotherapy.
|
28405493 |
2017 |
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The discovery of MYD88 L265P mutations in the vast majority of LPLs has had a major impact on the study of these lymphomas.
|
26454445 |
2016 |
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
|
22944768 |
2013 |
rs397507444
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In summary, this meta-analysis suggests that MTHFR A1298C polymorphism is associated with increased cervical cancer and lymphoma risk in Asians, and MTHFR A1298C polymorphism is associated with decreased colorectal cancer risk in Asians.
|
26156333 |
2016 |
rs397507444
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We have previously reported associations between lymphoma risk and germline polymorphisms in genes of methylenetetrahydrofolate reductase (MTHFR C677T and A1298C) and methionine synthase (MTR A2756G), finding the genotype other than the MTHFR 677CC/1298AA to confer a half-risk compared to the MTHFR 677CC/1298AA and a 3-fold higher risk with the MTR GG genotype than the AA/AG genotypes.
|
15551285 |
2004 |
rs397507444
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Recently, methylenetetrahydrofolate reductase (MTHFR C677T and A1298C) mutations were discovered to be associated with childhood acute lymphoblastic leukemia (ALL), as well as colon cancer, lymphoma, esophageal and stomach cancer.
|
16886608 |
2006 |
rs397507444
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Αnalysis according to lymphoma subtype revealed increased frequency of c. 677C > T TT genotype and T allele, as well as reduced prevalence of the c. 1298A > C C allele in the pSS non-MALT group compared to controls and patients without NHL.
|
28779180 |
2017 |
rs397507444
|
|
|
0.050 |
GeneticVariation |
BEFREE |
C677T and A1298C methylenetetrahydrofolate reductase (MTHFR) polymorphisms have been suggested to affect susceptibility to malignant lymphoma, possibly by altering DNA methylation.
|
14535593 |
2004 |
rs2230926
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The rs2230926 exonic variant was associated with an increased risk for pSS complicated by lymphoma (odds ratio, 3.36 [95% confidence interval, 1.34-8.42], and odds ratio, 3.26 [95% confidence interval, 1.31-8.12], vs controls and pSS patients without lymphoma, respectively; P = .011).
|
24159176 |
2013 |
rs2230926
|
|
|
0.040 |
GeneticVariation |
BEFREE |
However, the rs2230926 variant allele seems to confer a higher risk to develop lymphoma in pSS patients, while in RA patients, the presence of RF resulted significantly associated with the variant allele.
|
31534975 |
2019 |